Page 118 - ESHRE2019

Cumulative incidence of events (death, thromboembolic events, and major bleeding) in the rivaroxaban group (dotted and dashed line) and in the warfarin group (solid line).
Vittorio Pengo et al. Blood 2018;132:1365-1371
©2018 by American Society of Hematology
Rivaroxaban 11 events (+2)
Stroke 4 MI 3 Bleeds 4
Warfarin
2 events Both bleeds
Increased risk of thrombosis in APS patients treated with DOACs. Results from an international patient-level data meta-analysis.
Dufrost V Autoimmun Rev. 2018 Oct;17(10):1011-1021.
• 47 trials & 447 patients
• Rivaroxaban (n=290), dabigatran (144), apixaban (13)
• 73 (16%) had recurrent thrombosis
• Triple positive highest risk (56%)
• Previous arterial thrombosis (32%)
• DOACs NOT FOR ROUTINE USE IN APS
116
113